Imipenem and meropenem are among the drugs of choice used to treat nosocomial infections due to multidrug-resistant Acinetobacter baumannii isolates. However, their efficacy is being increasingly compromised by the emergence of carbapenem-hydrolyzing ␤-lactamases of molecular Ambler class B (metalloenzymes) and D enzymes (oxacillinases) (1, 2, 3, 12, 17) . Whereas the metalloenzymes are of IMP and VIM types, the carbapenem-hydrolyzing oxacillinases are members of three subgroups of enzymes: the OXA-23, OXA-24, and OXA-58 enzymes (2, 5, 9, 15, 16, 17) . Outbreaks of OXA-type carbapenemase-producing A. baumannii strains have been reported worldwide: OXA-24 in Madrid, Spain (4, 5); OXA-23 in Spain and in Curitiba, Brazil (2, 8); OXA-58 in Toulouse,
Imipenem and meropenem are among the drugs of choice used to treat nosocomial infections due to multidrug-resistant Acinetobacter baumannii isolates. However, their efficacy is being increasingly compromised by the emergence of carbapenem-hydrolyzing ␤-lactamases of molecular Ambler class B (metalloenzymes) and D enzymes (oxacillinases) (1, 2, 3, 12, 17) . Whereas the metalloenzymes are of IMP and VIM types, the carbapenem-hydrolyzing oxacillinases are members of three subgroups of enzymes: the OXA-23, OXA-24, and OXA-58 enzymes (2, 5, 9, 15, 16, 17) . Outbreaks of OXA-type carbapenemase-producing A. baumannii strains have been reported worldwide: OXA-24 in Madrid, Spain (4, 5) ; OXA-23 in Spain and in Curitiba, Brazil (2, 8) ; OXA-58 in Toulouse, France (11) ; and OXA-40 in Bilbao, Spain (13) . The aim of this study was to analyze the molecular mechanism of carbapenem resistance in A. baumannii strains isolated at the Centre Hospitalier de Polynésie Française (CHPF), the main hospital of Papeete, Tahiti, French Polynesia, that is located in the middle of the Pacific Ocean.
From March to May 2004, 24 carbapenem-resistant A. baumannii isolates were isolated from 24 patients hospitalized at the CHPF, a 353-bed tertiary care hospital. The patients' ages ranged from 8 to 80 years (mean age, 54 years). Nineteen patients (80%) were colonized and 5 were infected (20%) according to the French national recommendations, which derived from those of the Centers for Disease Control and Prevention (7, 10) . The sites of infection were urinary tract (2 patients), intravenous catheters (2 patients), and the respiratory tract (1 patient). The patients were scattered throughout the hospital, being mostly in the intensive care unit (41.7%), and the motives for hospital admission were diverse (Table 1) . Seventy-seven percent of the patients had a bacterial infection prior to the isolation of A. baumannii isolates and received an appropriate antibiotic treatment. Thirty-three percent of the patients died after A. baumannii isolation, but the death rate was 26.3% with colonization and 60% when the patient was infected. Infection with multidrug-resistant A. baumannii was considered by the clinicians to have contributed to the death of patient 3, despite amikacin and colistin treatment. The four other infected patients were cured from their infection without treatment. Two of them died from their underlying disease (patients 2 and 10; Table 1 ).
Isolates were identified using the API 32GN system (BioMérieux, Marcy l'Etoile, France). Pulsed-field gel electrophoresis (PFGE) was performed with ApaI-restricted wholecell DNAs embedded in 1% agarose plugs and separated in a 1% pulsed field-certified agarose gel using a contour-clamped homogeneous electric field DRII system (Bio-Rad, MarnesLa-Coquette, France), as previously described (11) . Routine antibiograms were determined by the disk diffusion method on Mueller-Hinton agar (Bio-Rad) and interpreted as recommended by the Clinical and Laboratory Standards Institute (6) . MICs of carbapenems were determined with E-tests (AB BIO-DISK, Solna, Sweden) performed on Mueller-Hinton agar plates (Oxoid, Basingstoke, United Kingdom) with incubation at 37°C for 24 h. DNA extractions (genomic and plasmid) and analysis, isoelectric focusing, and conjugation assays with rifampin-resistant A. baumannii strain CIP 7020 were performed as described previously (11) .
Genes coding for Ambler class B and D carbapenemases were sought by PCR using primers specific for the bla IMP (19) , bla VIM (19) , bla OXA-23 -like (9), bla OXA-26 -like (2), and bla OXA-58 genes (16) . Similarly, the class A ␤-lactamase bla TEM gene and the chromosomal class C ␤-lactamase bla AMPC gene were sought by PCR (11, 18) . The presence of ISAbaI inserted upstream of a bla AMPC -␤-lactamase gene was sought by PCR as previously described (14, 18) . PCR products were purified using a QIAquick PCR purification kit (QIAGEN, Courtaboeuf, France) and sequenced on both strands with an automated sequencer (ABI 3100; Applied Biosystems, Foster City, Calif.). The nucleotide and deduced amino acid sequences were analyzed with software available over the Internet (http: //www.ncbi.nlm.nih.gov/). Table 1 . The positions of molecular size markers in kilobases (M) are shown on the right side of the gel. Lanes C1, C2, C3, and C4 correspond to carbapenem-susceptible strains isolated during the study period. Lane C5 corresponds to A. baumanii strain C5, which was isolated in Montpellier in 1999 from a patient directly transferred from Papeete. The 24 A. baumannii isolates were resistant to all ␤-lactams, including carbapenems (with imipenem and meropenem MICs of Ͼ32 g/ml), ciprofloxacin, fosfomycin, tetracycline, chloramphenicol, and trimethoprim-sulfamethoxazole. The isolates remained susceptible to colistin (MIC, 0.5 g/ml), rifampin (MIC, 1 g/ml), and to aminoglycosides, except isolates 3, 4, 6, and 7, which were resistant to gentamicin and netilmicin.
The A. baumannii isolates were positive for bla OXA-23 -like, bla TEM -like, and the natural and chromosomally located bla AMPC genes. Sequencing of the amplified fragments confirmed the presence of bla OXA-23 , bla TEM-1 , and bla AMPC genes. As previously described, the bla OXA-23 gene was not embedded in a class 1 integron (9, 17, and data not shown). The genetic environment was similar to that of the prototype bla OXA-23 gene, with insertion sequence ISabaI inserted upstream of this gene, as revealed by PCR analysis (9, 14, 18) .
Isoelectric focusing confirmed that in addition to OXA-23 (pI 6.9), the chromosomal class C ␤-lactamase (pI Ͼ9.0) and TEM-1 (pI 5.4) were also expressed (data not shown).
Plasmid analysis revealed a 60-kb plasmid in all strains that was mobilizable to rifampin-resistant A. baumannii CIP 7020 (frequency of transfer, 10 Ϫ6 ). This plasmid expressed only ␤-lactamase OXA-23, and no additional resistance marker was identified according to results of routine antibiograms performed with the transconjugants and testing the same antibiotics as for the parental strains. The isolates from the different wards of the hospital gave similar PFGE patterns (Fig. 1) , differing by a maximum of three bands. Six different subtypes were observed, suggesting clonal dissemination of the isolates (Fig. 2) . The four carbapenem-susceptible control isolates from the same hospital differed from the carbapenem-resistant strain according to their PFGE patterns ( Fig. 1 and 2) .
Carbapenem-resistant A. baumannii strains have been isolated in Europe, Asia, and North and South America (1, 2, 4, 5, 8, 13, 16) . Outbreaks of OXA-23-producing A. baumannii isolates have also been reported in Spain and in Brazil (2, 4, 8) . (Fig. 3) . Interestingly, in 1999, A. baumannii strain C5 was identified at the university hospital of Montpellier (in southern France) from a French tourist previously hospitalized in a private hospital in Papeete. This strain had an identical antibiotic susceptibility profile and a similar PFGE pattern ( Fig. 1 and 2 ) and was OXA-23 positive. These data suggested that this strain could have been present for a much longer period of time on the island. After May 2004, the epidemic strain was still isolated in screening samples and in clinical specimens (Fig. 3) , but implementation of infection control measures (isolation precautions, chlorhexidine hand washing, and barrier protections) and thorough biodecontamination of the rooms of colonized patients led to control of the outbreak but did not eradicate the epidemic strain (Fig. 3) . The persistence of this strain is probably a consequence of frequent rehospitalization of colonized patients in the different wards. Indeed, the CHPF is the main hospital of the French Polynesian islands, dealing with acute care patients but also with long-term-care patients. The closest larger hospital is in Auckland, New Zealand, which is 2,600 miles away from Tahiti, thus limiting patient exchange. Overcoming the combination of clonal spread, multidrug resistance, and long-term-care patients that remain carriers is a challenge for the effective control of nosocomial A. baumannii infections.
